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Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic cell trans-
plantation (alloHCT). Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent
anti-inﬂammatory and immunosuppressive properties. We hypothesized that CBD may decrease GVHD
incidence and severity after alloHCT. We conducted a phase II study. GVHD prophylaxis consisted of cyclo-
sporine and a short course of methotrexate. Patients transplanted from an unrelated donor were given low-
dose antieT cell globulin. CBD 300 mg/day was given orally starting 7 days before transplantation until day
30. Forty-eight consecutive adult patients undergoing alloHCT were enrolled. Thirty-eight patients (79%) had
acute leukemia or myelodysplastic syndrome and 35 patients (73%) were given myeloablative conditioning.
The donor was either an HLA-identical sibling (n ¼ 28), a 10/10 matched unrelated donor (n ¼ 16), or a 1-
antigen-mismatched unrelated donor (n ¼ 4). The median follow-up was 16 months (range, 7 to 23). No
grades 3 to 4 toxicities were attributed to CBD. None of the patients developed acute GVHD while consuming
CBD. In an intention-to-treat analysis, we found that the cumulative incidence rates of grades II to IV and
grades III to IV acute GVHD by day 100 were 12.1% and 5%, respectively. Compared with 101 historical control
subjects given standard GVHD prophylaxis, the hazard ratio of developing grades II to IV acute GVHD among
subjects treated with CBD plus standard GVHD prophylaxis was .3 (P ¼ .0002). Rates of nonrelapse mortality
at 100 days and at 1 year after transplantation were 8.6% and 13.4%, respectively. Among patients surviving
more than 100 days, the cumulative incidences of moderate-to-severe chronic GVHD at 12 and 18 months
were 20% and 33%, respectively. The combination of CBD with standard GVHD prophylaxis is a safe and
promising strategy to reduce the incidence of acute GVHD. A randomized double-blind controlled study is
warranted. (clinicaltrials.gov: NCT01385124)
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION transplanted from an HLA-matched sibling donor and 50%
Despite prophylactic immunosuppressive treatment,
graft-versus-host disease (GVHD) remains a major cause of
morbidity and mortality after allogeneic hematopoietic cell
transplantation (alloHCT), affecting 30% to 50% of patientsedgments on page 1775.
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ty for Blood and Marrow Transplantation.to 70% of patients transplanted from an HLA-matched un-
related donor [1-4]. The ability to prevent GVHD is of
utmost importance, because treatment for established
GVHD remains suboptimal. In a survey, GVHD and its con-
sequences were the most important reason physicians were
reluctant to use transplantation [5]. Thus, developing
innovative strategies to prevent and treat GVHD is a major
unmet need.
Cannabis sativa, commonly known as marijuana, pos-
sesses a wide range of potent anti-inﬂammatory and
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subjects has been associated with a decrease in lymphocyte
proliferative response to mitogenic stimulation and IL-2
levels and an increase in IL-10 and transforming growth
factor-b1 levels [6]. In a recent prospective placebo-
controlled study, cannabis smoking induced a signiﬁcant
clinical response in patients with refractory Crohn’s disease
[7]. Cannabis contains more than 60 chemical compounds
classiﬁed as cannabinoids [8]. Two cannabinoids in particular
have been subjects of most studies examining medical uses:
D9-tetrahydrocannabinol (THC) and cannabidiol (CBD). In an
experimental murine model, THC, the main psychoactive
ingredient of marijuana, was shown to be effective in both
the prevention and treatment of GVHD [9]. Its administration
led to reduced tissue injury to the liver and intestine, to early
recovery from body weight loss associated with GVHD, and
to increased mice survival. THC-treated GVHD mice had
signiﬁcantly decreased levels of IL-2 and INF-g. On a cellular
level, THC treatment reduced the expansion of donor-
derived effector T cells and increased the number of
Foxp3þ regulatory T cells. Nevertheless, despite its prom-
ising therapeutic potential, the unwanted psychoactive ef-
fects of THC limit its consideration as a potential medication
for GVHD prophylaxis.
CBD, in contrast, which contributes up to 40% of cannabis
extract, does not produce psychoactive effects and is well
tolerated by humans evenwhen taken over extended periods
of time and thus has the potential for both clinical research
and therapeutic use [10-17]. Similar to THC, CBD possesses
potent anti-inﬂammatory and immunosuppressive proper-
ties. Its administration results in attenuation of clinical dis-
ease in animal models of various inﬂammatory diseases,
including multiple sclerosis, rheumatoid arthritis, inﬂam-
matory bowel disease, and diabetes mellitus [18-23]. These
effects are mediated by T cell attrition and by inhibition of
pro-inﬂammatory cytokine release (tumor necrosis factor-a,
INF-g, IL-1b, IL-6, and IL-17) and stimulation of anti-
inﬂammatory cytokine production (IL-4, IL-5, IL-10, and IL-
13) [19-25]. Furthermore, cannabinoids have recently been
shown to reduce the capacity of dendritic cells to migrate to
secondary lymphoid organs and activate naive T cells [26].
Based on these experimental and clinical observations, we
conducted a phase II study to assess the safety and efﬁcacy of
CBD in the prevention of acute GVHD.METHODS
This prospective, single-center phase II clinical trial was approved by the
institutional review board of the Rabin Medical Center (RMC). Written
informed consent was obtained from patients before enrollment.Inclusion and Exclusion Criteria
Patients were eligible for the study if they were 18 years and older and
had an available 10/10 HLA-matched or 1-antigen-mismatched related or
unrelated donor. Patients were excluded if they had a mental disorder, were
actively consuming illicit drugs, or were consuming cannabis during the 3
months before transplantation. Patients receiving cord blood or hap-
loidentical transplantations were excluded.Conditioning Regimens
Myeloablative conditioning included total body irradiation 12 Gy plus
i.v. cyclophosphamide 120 mg/kg or i.v. busulfan 12.8 mg/kg plus either i.v.
cyclophosphamide 120 mg/kg or i.v. ﬂudarabine 160 mg/m2. Reduced-
intensity conditioning was composed of i.v. ﬂudarabine 150 mg/m2 with
either i.v. busulfan 6.4 mg/kg or i.v. melphalan 100 mg/m2. Non-
myeloablative conditioning comprised total body irradiation 2 Gy plus i.v.
ﬂudarabine 90 mg/m2. All patients received granulocyte colony-stimu-
lating-factor mobilized peripheral blood stem cell grafts.GVHD Prophylaxis
All patients received standard GVHD prophylaxis consisting of cyclo-
sporine twice daily starting on day 1 with target trough levels of 200 to
400 ng/mL and a short course of methotrexate (MTX) (15 mg/m2 on day 1
and 10mgm2 on days 3 and 6). Patients transplanted from unrelated donors
received antieT cell globulin (Fresenius, Germany) at a low dose of 5 mg/kg
on days 3 to 1 [27].
The investigational agent, CBD (STI Pharmaceuticals, Essex, UK), was
dissolved in olive oil at a concentration of 2.5% and orally administered at a
ﬁxed dose of 150 mg twice daily, starting 7 days before transplantation until
day 30. Dose and duration of CBD administration were based on doses
previously safely used in several clinical trials in the nontransplant setting
[10-17].
Supportive Care
All patients received ﬁlgrastim (granulocyte colony-stimulating factor)
at a dose of 5 mg/kg/day from day 7 until neutrophil engraftment, infection
prophylaxis according to institutional guidelines [28], and ursodeoxycholic
for sinusoidal obstruction syndrome prevention.
Endpoints
Endpoints were assessed based on intention-to-treat analysis. Primary
endpoints were safety and cumulative incidence rates of grades II to IV and
grades III to IV acute GVHD by day 100. Secondary endpoints were cumu-
lative incidence rates of acute GVHD by day 200, overall and moderate to
severe chronic GVHD, nonrelapse mortality (NRM), relapse incidence, and
overall survival.
Acute GVHD was assessed by using the consensus grading system, and
suspected cases of GVHD were histologically conﬁrmed [29]. Chronic GVHD
was assessed according to the National Institutes of Health consensus
criteria [30]. Donor chimerism in bone marrow was measured by XY-
ﬂuorescence in situ hybridization analysis in sex-mismatched pairs and by
DNA ampliﬁcation of polymorphic microsatellite regions in sex-matched
pairs as previously described [31,32].
We compared the outcomes of the study group with a control group of
101 adult patients whowould havemet the protocol inclusion and exclusion
criteria and consecutively underwent alloHCT and were treated by the same
medical team at the RMC between May 2007 and August 2012. This his-
torical cohort received the same standard GVHD prophylaxis consisting of
cyclosporine and a short course of MTX without CBD. Side effects possibly
attributed to CBD were graded according to the Common Terminology
Criteria for Adverse Events (CTCAE v4.0) classiﬁcation [33].
Statistical Considerations
Cohort sample size (n¼ 48) was calculated to demonstrate a reduction of
50% in the occurrence of grades II to IV acute GVHD by dayþ100with a power
of 80% and a Type I error of .05. Neutrophil and platelet recoverywere deﬁned
as the ﬁrst of 3 days with absolute neutrophil counts 500/mL and the ﬁrst of
7 days with an unsupported platelet count  20,000/mL, respectively.
NRM was deﬁned as death in remission. Death was treated as a
competing risk in the analyses of relapse and progression and acute and
chronic GVHD. Relapse and progression were treated as a competing risk
when analyzing NRM. Probabilities of overall survival and disease-free
survival were calculated using the Kaplan-Meier estimates. The log-rank
test was used for univariate comparisons. Categorical variables of study
and historical cohorts were compared using the chi-square or Fisher Exact
test, as appropriate. All P values are 2-sided. Statistical analyses were per-
formed using SPSS version 21 (SPSS Inc., Chicago, IL, USA) and Prism version
5.0 (GraphPad, San Diego, CA, USA).
RESULTS
Patients
From September 2012 through January 2014, 50 consec-
utive unselected adult patients were evaluated for enroll-
ment. Two patients refused informed consent. Among 48
enrolled patients, 1 patient with acute leukemia declined
informed consent 2 days after starting CBD; a second patient
with aplastic anemia had primary graft failure and received a
second transplant for which CBD was not administered.
These 2 patients were included in the intention-to-treat
analyses. Baseline characteristics and transplantation pa-
rameters of the 48 patients are depicted in Table 1.
Median patient age was 56 years (range, 22 to 73), and 19
patients (40%) were 60 years or older. Most patients (n ¼ 38,
79%) had acute leukemia or myelodysplastic syndrome.
Table 1
Patient and Transplantation Characteristics
Characteristic All Cohort
(N ¼ 48)
Historical
Cohort
(N ¼ 101)
P
Patient characteristics
Age, yr, median (range) 56 (22-73) 51 (19-71) .07
Female (%) 17 (35) 40 (40) .7
HCT-CI > 2 (%) 10 (21) 12* (39) .13
CMV þ/þ (%) 35 (73) 84 (84) .8
Disease (%) .9
Acute leukemia 33 (69) 74 (74)
AML 26 63
ALL 7 11
MDS 5 (10.5) 6 (6)
LPD 7 (14.5) 12 (12)
Other 3 (6) 9 (9)
Disease risk according to the
reﬁned DRI (%)
.19
Low 2 (4) 10 (10)
Intermediate 24 (51) 38 (38)
High 15 (32) 45 (45)
Very high 6 (13) 8 (8)
Donor characteristics
Matched sibling 28 (58) 58 (58) 1
Full matched unrelated 16 (33) 41 (41) 1
One-allele/antigen-mismatched
unrelated (%)
4 (9) 2 (2) .18
Female to male (%) 7 (15) 18 (18) .5
Preparative regimen .6
Myeloablative (TBI/Cy or Bu/Cy) 11 (23) 26 (26)
Myeloablative reduced toxicity 24 (50) 42 (42)
Reduced intensity 13 (27) 33 (33)
Antithymocyte globulin 20 (42) 43 (43) 1
Transfused CD34  106/kg,
median (range)
6 (2.7-13) 6.8 (2.1-9) .8
HCT-CI indicates hematopoietic cell transplantation comorbidity index;
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; LPD,
lymphoproliferative disease; TBI, total body irradiation; Cy, cyclophospha-
mide; Bu, busulfan.
* Of 31 patients with available data.
Table 2
Organ-Speciﬁc Involvement by Acute GVHD
(%) Patients (%) Patients in P
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2), 51% (n ¼ 24), 32% (n ¼ 15), and 13% (n ¼ 6) had low-,
intermediate-, high-, and very-high-risk disease, respec-
tively, according to the reﬁned Disease Risk Index (DRI) for
alloHCT (Table 1) [34]. Four patients underwent a prior
autologous stem cell transplantation (multiple myeloma, n¼
1; non-Hodgkin lymphoma, n ¼ 2; Hodgkin lymphoma, n ¼
1). Thirty-ﬁve patients (73%) received a myeloablative con-
ditioning and 20 patients (42%) received allografts from
unrelated donors (10/10 match, n ¼ 16; 9/10 match, n ¼ 4).
Seven male patients (15%) received allografts from a female
donor (Table 1). The median follow-up of survivors was 16
months (range, 7 to 23).in the CBD
Cohort (N ¼ 48)
the Control
Cohort (N ¼ 101)
Skin .0033
Stage 1 0 12
Stage 2 6 17
Stage 3 6 5
Stage 4 0 1
Upper GIT 12 33 .0057
Lower GIT <.0001
Stage 1 4 34
Stage 2 0 4Compliance and Toxicity
The overall compliance with the protocol was good, with
32 patients (70%) taking 100% of doses. Median dose
compliance among noncompliant patients was 86% (range,
43% to 96%). Noncompliance with study medication was
mainly due to mucositis and nausea. No grades 3 to 4 non-
hematological toxicities related to CBD were observed.Stage 3 4 2
Stage 4 4 4
Liver .34
Stage 1 2 3
Stage 2 0 3
Stage 3 0 1
Stage 4 2 3Engraftment and Chimerism
In all, 47 patients (98%) achieved primary engraftment.
One female patient with aplastic anemia had a primary graft
failure. This patient subsequently had a second transplant
from the same donor without reconditioning and engraftedproperly. She did not receiveMTX and CBD during the second
transplant.
The median time to absolute neutrophil counts  500/mL
was 11 days (range, 10 to 22). The median time to unsup-
ported platelet counts  20,000/mL was 16 days (range, 13 to
33). None of the patients experienced secondary graft failure.
Excluding the patient with primary graft failure, the median
percentage of donor whole marrow chimerism was 99%
(range, 91% to 100%) on day 30 and 100% (range, 95% to 100%)
on day 200.Graft-versus-Host-Disease
All 48 patients were assessable for acute GVHD. None of
the patients developed acute GVHD while consuming CBD
(ie, before day 30). One patient developed grade I acute
GVHD, and 7 patients developed grades II to IV acute GVHD
after CBD discontinuation. Two patients had involvement of
the gastrointestinal tract (GIT) only, 3 patients had involve-
ment of the GIT and skin, 1 patient had involvement of the
GIT and liver, and 1 patient had involvement of the GIT, skin,
and liver. Among the 7 patients with GIT involvement, 2
patients had only involvement of the lower GIT and 5 pa-
tients had involvement of both the upper and lower GIT.
Organ-speciﬁc stages of acute GVHD are depicted in Table 2.
Median time to onset of grades II to IV acute GVHDwas 60
days (range, 41 to 150). Based on an intention-to-treat
analysis, cumulative incidence rates of grades II to IV acute
GVHD by days 100 and 200 were 12.1% (95% conﬁdence in-
terval [CI], 1% to 41%) and 14.8% (95% CI, 1% to 45%), respec-
tively (Figure 1). Four patients developed grades III to IV
acute GVHD. Among them, 1 patient developed steroid-
refractory grade III acute GVHD on day 46, which was sub-
sequently treated with extracorporal photopheresis and
gradually improved. A second patient developed grade III
acute GVHD on day 71 fromwhich he recovered. This patient
subsequently had a relapse of leukemia and died on day 186
after alloHCT. A third patient with aplastic anemia stopped
CBD on day 8 because of severe mucositis, had primary graft
failure, and hence received a second transplant on day 32 for
which MTX and CBD were not administered. The patient
developed grade IV acute GVHD on day 106 and died from
sepsis on day 138 after alloHCT. The fourth patient developed
grade IV acute GVHD on day 150, upon cessation of cyclo-
sporine, and died of sepsis on day 179 after alloHCT.
Figure 1. Cumulative incidence of acute GVHD.
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days 100 and 200 were 5% (95% CI, 1% to 45%) and 8% (95% CI,
2% to 51%), respectively (Figure 1).
Among patients surviving more than 100 days after
alloHCT (n ¼ 41), chronic GVHD occurred in 15 patients
(overlap, n ¼ 3; classic, n ¼ 12), with a median time to onset
of 159 days (range, 110 to 486). Chronic GVHD was classiﬁed
as mild, moderate, and severe in 7, 1, and 7 patients,
respectively. Notably, 6 of 7 patients with severe chronic
GVHD had moderate (score 2) lung involvement.
The cumulative incidence rates of overall and moderate-
to-severe chronic GVHD at 1 year were 49.7% (95% CI, 26%
to 65%) and 20% (95% CI, 5% to 52%), respectively (Figure 2).
The cumulative incidence rates of overall and moderate-to-
severe chronic GVHD at 18 months were 58% (95% CI, 36%
to 69%) and 33% (95% CI, 12% to 57%), respectively (Figure 2).Comparison of Acute GVHD Incidence between Study and
Control Groups
There was no signiﬁcant difference between subjects
treated with CBD and the historical control patients treated
at the RMC with respect to baseline characteristics and risk
factors for GVHD (Table 1). The cumulative incidence rates of
grades II to IV and grades III to IV acute GVHD by day 100
among the 101 historical control patients were 46% and 10%,
respectively. Compared with subjects given standard GVHD
prophylaxis, the hazard ratios of developing grades II to IV
and grades III to IV acute GVHD by day 100 among subjects
treated with CBD plus standard GVHD prophylaxis were .3
(95% CI, .2 to .6; P ¼ .0002) and .6 (95% CI, .2 to 1.8; P ¼ .3),
respectively. Nevertheless, this did not translate into statis-
tically signiﬁcant difference in NRM at 12 months (13.4%
versus 20%, P¼ .95). Median time for developing acute GVHD
in the control group was 20 days (range, 9 to 137). The me-
dian time to onset of acute GVHDwas signiﬁcantly shorter inFigure 2. Cumulative incidence of chronic GVHD.the control group compared with the CBD group (20 versus
60 days, P ¼ .001). Furthermore, the 2 groups differed
signiﬁcantly with respect to organ-speciﬁc involvement by
acute GVHD as depicted in Table 2. Patients treated with CBD
had less often skin (P ¼ .0033), upper GIT (P ¼ .0057), and
lower GIT (P < .0001) involvement.
Infections and Transplantation Related Toxicities during
Aplasia
Seven patients (15%) had grades 3 to 4 mucositis, mostly
involving the upper GIT. Eight patients had microbiology
documented infections during aplasia (Escherichia coli
bacteremia, n ¼ 5; Pseudomonas bacteremia, n ¼ 1; Clos-
tridium difﬁcileeassociated diarrhea, n ¼ 2). Of these pa-
tients, 1 patient had also Candida glabrata candidemia. One
of the patients with sepsis developed sinusoidal obstruction
syndrome. Another patient had fatal cardiac arrhythmia
associated with sinusoidal obstruction syndrome. By day 28,
8 of 47 patients at risk had cytomegalovirus (CMV) reac-
tivation; all were treated with pre-emptive valganciclovir. By
day 100, 12 additional patients of 44 at risk had CMV reac-
tivation. None of the patients developed CMV disease.
Relapse and Survival
Among the 16 patients who relapsed, 11 had high- or
very-high-risk disease according to the reﬁned DRI for allo-
geneic stem cell transplantation [34] and 3 had acute
myeloid leukemia with FLT3-ITD mutation [35]. The cumu-
lative incidence of relapse at 1 year post-transplantationwas
41% (95% CI, 19% to 55%) (Figure 3). Outcomes were un-
changed when analyzed per-protocol. There were 3 early
nonrelapse deaths by day 28: 1 patient with refractory
angioimmunoblastic Tcell lymphoma and ongoing infections
at transplantation developed pseudomonas bacteremia, 1
patient with acute myeloid leukemia had polymicrobial
sepsis associated with sinusoidal obstruction syndrome, and
1 patient with refractory blastic natural killer cell lymphoma
had a fatal arrhythmia associatedwith sinusoidal obstruction
syndrome. There were 2 nonrelapse-related late deaths on
days 136 and 179, respectively, both due to sepsis associated
with grade IV late-onset acute GVHD as previously described.
In all, only 2 patients on an intention-to-treat analysis and 1
patient per-protocol analysis died from GVHD and its com-
plications. Cumulative incidence rates of NRM by day 100Figure 3. Cumulative incidence of relapse.
Figure 5. Kaplan Meier estimation of OS.
M. Yeshurun et al. / Biol Blood Marrow Transplant 21 (2015) 1770e17751774and by 1 year after transplantation were 8.6% (95% CI, 0 to
43%), and 13.4% (95% CI, 2% to 45%), respectively (Figure 4).
Overall survival rates by day 100 and 1 year after trans-
plantation were 85% (95% CI, 65% to 91%) and 68% (95% CI,
55% to 80%), respectively (Figure 5).
DISCUSSION
In this study, we showed that the addition of CBD to
standard GVHD prophylaxis consisting of cyclosporine and
MTX resulted in low cumulative incidence rates of both
grades II to IV (12.1%) and grades III to IV (5%) acute GVHD by
day 100. In view of patient (median age 56 years), donor
(unrelated, 43%; mismatched unrelated, 9%), and transplant
characteristics (myeloablative conditioning, 73%), one could
anticipate signiﬁcantly higher rates of both acute GVHD
(more closely to 50%) and NRM (20% to 30%) [4,36,37].
Indeed, among the 101 control subjects treated by the same
medical team at the RMC and given standard GVHD pro-
phylaxis consisting of cyclosporine and MTX, the cumulative
incidence rates of grades II to IV and grades III to IV acute
GVHD by day 100 were 46% and 10%, respectively. Compared
with control subjects, the hazard ratio of developing grades II
to IV acute GVHD by day 100 among subjects given the same
standard GVHD prophylaxis plus CBD was .3 (P ¼ .0002).
There was also a lower hazard for developing grades III to IV
acute GVHD, but this did not reach statistically signiﬁcance
(hazard ratio .6, P ¼ .3). Nevertheless, the favorable impact of
CBD on acute GVHD incidence did not translate into a
signiﬁcantly lower NRM rate (13.4% versus. 20%, P ¼ .95).
Remarkably, none of the patients developed acute GVHD
while consuming CBD.Moreover, themedian time to onset of
acute GVHD was signiﬁcantly longer in the CBD group
compared with the control group (60 versus 20 days,
P ¼ .001).
The low incidence rates of acute GVHD and moderate-to-
severe chronic GVHDwitnessed among patients treated with
CBD in this study were of a similar magnitude to the inci-
dence rates of GVHD revealed in recent phase I/II studies
among patients treated with novel agents like maraviroc
(CCR5 antagonist) [38] and bortezomib (proteasome inhibi-
tor) [39] and compared favorably with incidence rates of
GVHD displayed among patients treated with vorionostat
(histone deacetylase) [40].
In view of the high-risk disease characteristics of this
study population, of which 45% had a high or very-high DRIFigure 4. Cumulative incidence of NRM.at transplantation with an expected 2-year survival rate of
33% and 23%, respectively, the observed 1-year cumulative
incidence of relapse of 41% was not higher than expected
[34]. This in line with the common notion that heightened
graft-versus-tumor effect correlates more substantially with
chronic GVHD than with acute GVHD [37].
The cumulative incidence rates of overall and moderate-
to-severe chronic GVHD were 49% and 20%, respectively, at
12 months and 58% and 33%, respectively, at 18 months.
Although mild chronic GVHD does not signiﬁcantly impair
daily living, moderate-to-severe chronic GVHD has profound
impact on quality of life and is a major concern. Despite the
potential beneﬁcial effect of chronic GVHD on disease
relapse, the favorable graft-versus-tumor effect associated
with chronic GVHD had previously been shown to be offset
by increased NRM [37]. Thus, future efforts should be
directed toward more effective prevention of the clinically
detrimental types of chronic GVHD (ie, the moderate and
severe grades) yet without mitigating the graft-versus-
tumor effect. Given that CBD was safe and well tolerated
and in light of the encouraging results of the current trial, our
institution is planning a phase II trial aiming to explore if a
longer exposure to CBD may further reduce late-onset acute
GVHD and/or chronic GVHD. Additionally, CBD has been
shown to induce apoptosis of myeloid and lymphoid
leukemic cells both in vitro and in vivo [41-43], and although
never tested before in vivo in humans, prolonged exposure to
CBD may potentially reveal a favorable antileukemic effect.
CBD was safely administered in combination with the
standard GVHD prophylaxis composed of cyclosporine and
short-course MTX. CBD was well tolerated, and no severe
adverse events were attributed to its consumption. This is in
accordance with safety data previously reported on CBD
administered to humans, evenwith 3- to 4-fold higher doses
and even when taken over extended periods of time [10-17].
The fact that 1 patient with aplastic anemia had primary
graft failure should probably not be attributed to CBD
because basically the rate of graft failure after alloHCT for
aplastic anemia is in the range of 10% to 20% [44]. Further-
more, this was the only case out of 48 patients who had a
graft failure.
This study has several limitations. First, the study is
limited by its single-arm design, and retrospective compar-
isons with historical control subjects may potentially be
biased. Second, despite ample data in murine models on the
M. Yeshurun et al. / Biol Blood Marrow Transplant 21 (2015) 1770e1775 1775mechanism of action of CBD in autoimmune and inﬂamma-
tory diseases [12-17], the present study is lacking concomi-
tant supportive cytokine and cellular data that would
reinforce our clinical observations. Third, we lack pharma-
cokinetic and pharmacodynamic data to support adequate
delivery of oral CBD in the context of transplantation. Hence,
we plan to tackle these issues in a subsequent study.
In conclusion, this prospective, single-center study
showed for the ﬁrst time the potential role of CBD in the
prevention of GVHD. We intend to validate these promising
results in a prospective, placebo-controlled, double blind,
randomized study.
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